In addition, the proliferation rate of thyroid cancer cells with RET kinase mutations has been shown to be inhibited by AST-487 treatment [15], which is interesting since thyroid cancer has a high rate of hTERT promoter mutations [10]. This evidence concerns the gene RET and thyroid gland carcinoma.